GALT Galectin Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: GALT

Price (delayed)

$1.95

Market cap

$120.6M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.76

Enterprise value

$161.38M

Galectin Therapeutics is dedicated to developing novel therapies to improve the lives of patients with chronic liver disease and cancer. Galectin's lead drug belapectin (formerly known as GR-MD-02) is a ...

Highlights
Galectin Therapeutics's quick ratio has increased by 18% YoY and by 7% QoQ
GALT's equity has dropped by 119% year-on-year
The debt has soared by 106% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.galectintherapeutics.com
Peers: MEIP MRTX MNOV

Key stats

What are the main financial stats of GALT
Market
Shares outstanding
61.85M
Market cap
$120.6M
Enterprise value
$161.38M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$43.07M
EBITDA
-$43.04M
Free cash flow
-$35.5M
Per share
EPS
-$0.76
Free cash flow per share
-$0.59
Book value per share
-$0.88
Revenue per share
$0
TBVPS
$0.37
Balance sheet
Total assets
$22.16M
Total liabilities
$73.04M
Debt
$61.14M
Equity
-$52.6M
Working capital
$11.09M
Liquidity
Debt to equity
-1.16
Current ratio
2.05
Quick ratio
1.94
Net debt/EBITDA
-0.95
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-217%
Return on equity
N/A
Return on invested capital
-98.3%
Return on capital employed
-370%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

GALT stock price

How has the Galectin Therapeutics stock price performed over time
Intraday
-0.51%
1 week
-3.94%
1 month
-3.47%
1 year
53.54%
YTD
72.57%
QTD
1.56%

Financial performance

How have Galectin Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$39.14M
Net income
-$45.32M
Gross margin
N/A
Net margin
N/A
The company's net income fell by 28% YoY and by 14% QoQ
The operating income has declined by 11% year-on-year and by 2.7% since the previous quarter

Growth

What is Galectin Therapeutics's growth rate over time

Valuation

What is Galectin Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Galectin Therapeutics's EPS has decreased by 29% YoY and by 15% QoQ
GALT's equity has dropped by 119% year-on-year

Efficiency

How efficient is Galectin Therapeutics business performance
The ROA has plunged by 82% YoY and by 8% from the previous quarter
GALT's ROIC is up by 38% YoY and by 7% QoQ

Dividends

What is GALT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for GALT.

Financial health

How did Galectin Therapeutics financials performed over time
Galectin Therapeutics's total assets is 70% less than its total liabilities
The total liabilities has soared by 81% YoY and by 2.6% from the previous quarter
Galectin Therapeutics's total assets has increased by 24% YoY and by 10% from the previous quarter
GALT's equity has dropped by 119% year-on-year
The debt has soared by 106% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.